



Dkt. #639-B-PCT-US

1Pw

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nai-Kong CHEUNG

U.S. Serial No.: 10/621,027, continuation-in-part of
International Application No.
PCT/US02/01276, filed January 15, 2002,
claiming benefit of U.S. Serial No.
60/261,911, filed January 16, 2001

Filed Date : July 16, 2003

For : THERAPY-ENHANCING GLUCAN

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

May 12, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Supplemental Information Disclosure Statement in accordance with their duty of disclosure under 37 C.F.R. §1.56. Applicant originally filed an Information Disclosure Statement for the above-identified application on July 16, 2003 and Supplemental Information Disclosure Statements on April 12, 2004, September 24, 2004, November 8, 2004, November 22, 2004 and March 25, 2005. Applicant would like to direct the Examiner's attention to the following references which are listed below as **Exhibits 1-10** and on Forms PTO/SB/08A (**Exhibit A**, 1 page) and PTO/SB/08B (**Exhibit B**, 1 page).

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 2

The following references are attached:

1. Search Report prepared by the Norwegian Patent Office, dated May 4, 2005 [Exhibit 1]
2. Hong et al., "Mechanism by Which Orally Administered β -1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models", Journal of Immunology, Vol. 173, No. 5, Pages 797-806 (2004) [Exhibit 2]
3. Ostroff et al., "Immune-Enhancing Effects of Oral Yeast β 1,3/1,6 Glucans", American Chemical Society, Vol. 225, No. 1-2, pp. AGFD 8 (2003) [Exhibit 3]
4. Allendorf et al., "Macrophages shuttle orally administered β -glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models", FASEB Journal, Vol. 17, No. 7, Page C128 (2004) [Exhibit 4]
5. Papila et al., "The Effect of oral β -glucan in addition to systemic chemotherapy on the leukocyte values with oral mucositis in the patients with head-neck tumors", International Review of Allergology & Clinical Immunology, Vol 10, No. 2, Pages 59-61 (2004) [Exhibit 5]
6. U.S. Patent Application Publication No. US 2004/0248772 A1 for Akikuni Yagita, December 9, 2004. "Anticancer Compositions" [Exhibit 6]
7. U.S. Patent Application Publication No. US 2004/0266726 A1 for Akikuni Yagita, December 30, 2004. "Anticancer Compositions" [Exhibit 7]

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 3

8. U.S. Patent No. US 4,761,402 for Williams et al., August 2, 1988. "Methods and Compositions for Prophylactic and Therapeutic Treatment of Infections" **[Exhibit 8]**
9. U.S. Patent No. US 4,818,752 for Williams et al., April 4, 1989. "Soluble Phosphorylated Glucan: Methods and Compositions for Treatment of Neoplastic Diseases" **[Exhibit 9]**
10. International Patent Application Publication No. WO 98/39013 for Peregrine Pharmaceutical, Inc. et al., September 11, 1998 for "Composition and Method for Treating Cancer and Immunological Disorders Resulting in Chronic Conditions" **[Exhibit 10]**

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 4

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

I hereby certify that this paper is being deposited this date with the U.S. Postal Service with sufficient postage for first class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Albert Wai-Kit Chan

5/12/05

Albert Wai-Kit Chan
Reg. No. 36,479

Date

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 357-8836
Fax: (718) 357-8615
E-mail: kitchanlaw@aol.com



Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 144B-10

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong Cheung
Art Unit	1623
Examiner Name	Jason H. Johnsen
Attorney Docket Number	639-B-PCT-US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	10	WO 98/39013	09-11-1998	Peregrine Pharmaceutical, Inc. et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO/SB/08B (04-03)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong Cheung
Art Unit	1623
Examiner Name	Jason H. Johnsen
Attorney Docket Number	639-B-PCT-US

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Search Report prepared by the Norwegian Patent Office, dated May 4, 2005	
	2	Hong et al., "Mechanism by Which Orally Administered β -1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models", Journal of Immunology, Vol. 173, No. 5, Pages 797-806 (2004)	
	3	Ostroff et al., "Immune-Enhancing Effects of Oral Yeast β 1,3/1,6 Glucans", American Chemical Society, Vol. 225, No. 1-2, pp. AGFD 8 (2003)	
	4	Allendorf et al., "Macrophages shuttle orally administered β -glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models", FASEB Journal, Vol. 17, No. 7, Page C128 (2004)	
	5	Papila et al., "The Effect of oral β -glucan in addition to systemic chemotherapy on the leukocyte values with oral mucositis in the patients with head-neck tumors", International Review of Allergology & Clinical Immunology, Vol 10, No. 2, Pages 59-61 (2004)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.